on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group, Inc.: Disclosure on Avadel Pharmaceuticals plc
The Vanguard Group, Inc. has disclosed its interest in Avadel Pharmaceuticals plc, confirming the ownership and control of 5,527,806 ordinary shares, representing 5.68% of the company's shares. These details were submitted under Form 8.3 concerning regulations by the Irish Takeover Panel.
The disclosure shows a recent purchase of 665 ordinary shares at a price of 23.02 USD per unit. This activity reflects Vanguard's strategy in managing its interests within Avadel Pharmaceuticals.
No additional derivatives, options, or agreements affecting the securities have been reported. Similarly, there are no indemnities or arrangements inducing dealing activity, ensuring transparency in the declaration process.
Vanguard's latest position showcases its significant stake in Avadel, marking a continued commitment to its investment strategy.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news